Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Overview of attention for article published in Journal of Clinical Oncology, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 4 news outlets
blogs: 1 blog
twitter: 22 X users
reddit: 2 Redditors

video: 1 YouTube creator
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 23 X posts from 22 X users, with an upper bound of 135,137 followers.

RT @cancer_evolve: ENDOMETRIAL: maintenance therapy with the XPO1 inhibitor selinexor may benefit patients with TP53 wild-type disease; con…

ENDOMETRIAL: maintenance therapy with the XPO1 inhibitor selinexor may benefit patients with TP53 wild-type disease; confirmatory studies are required. https://t.co/7DDTqFIZag

exportin-1 阻害薬である Selinexor の子宮体癌に対する維持療法は、TP53 wild type の場合に効果がある可能性がある。全体集団では有意差を得られなかった。第3相臨床試験 ENGOT-EN5/GOG-3055/SIENDO の結果。 https://t.co/tkJDqcryuh

RT @JCO_ASCO: 🎯Oral selinexor is active as maintenance therapy after 1st-line chemotherapy for advanced or recurrent #EndometrialCancer, es…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 19 additional X posts.